These data extended previous findings on the pathogenic role of myostatin in tumors [17,42–44], sarcopenia [45], neuromuscular diseases [46,47] and COPD [48–50], and support the notion that myostatin participates in the pathogenic process of skeletal muscle damage. This evidence concerns the gene MSTN and sarcopenia.